KR101419085B1 - 융합 치환된 아미노피롤리딘 유도체 - Google Patents
융합 치환된 아미노피롤리딘 유도체 Download PDFInfo
- Publication number
- KR101419085B1 KR101419085B1 KR1020097013835A KR20097013835A KR101419085B1 KR 101419085 B1 KR101419085 B1 KR 101419085B1 KR 1020097013835 A KR1020097013835 A KR 1020097013835A KR 20097013835 A KR20097013835 A KR 20097013835A KR 101419085 B1 KR101419085 B1 KR 101419085B1
- Authority
- KR
- South Korea
- Prior art keywords
- group
- hydrate
- salt
- formula
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CN(C(*)C1(*)*)C(*)C1(*)N(*)* Chemical compound CN(C(*)C1(*)*)C(*)C1(*)N(*)* 0.000 description 37
- BAHCVLFBVLHHJZ-VXGBXAGGSA-N CC(C)(C)OC(N[C@@]1(CC2)[C@@]2(C)CNC1)=O Chemical compound CC(C)(C)OC(N[C@@]1(CC2)[C@@]2(C)CNC1)=O BAHCVLFBVLHHJZ-VXGBXAGGSA-N 0.000 description 1
- HQKKIOBHAWQJIT-BXKDBHETSA-N CC(C)(C)OC(N[C@@]12C=CC[C@@H]1CNC2)=O Chemical compound CC(C)(C)OC(N[C@@]12C=CC[C@@H]1CNC2)=O HQKKIOBHAWQJIT-BXKDBHETSA-N 0.000 description 1
- LKJJGJIZTFOFTH-SECBINFHSA-N CC(C)(C)OC(N[C@H](CNCCCC1)C1(F)F)=O Chemical compound CC(C)(C)OC(N[C@H](CNCCCC1)C1(F)F)=O LKJJGJIZTFOFTH-SECBINFHSA-N 0.000 description 1
- KMAYLVCSDLCILB-LDYMZIIASA-N CC(C)(C)OC(N[C@](CC1)(CNC2)[C@@H]2C1(F)F)=O Chemical compound CC(C)(C)OC(N[C@](CC1)(CNC2)[C@@H]2C1(F)F)=O KMAYLVCSDLCILB-LDYMZIIASA-N 0.000 description 1
- LTYWGNZNVSBEFB-YGOYTEALSA-N CC(C)(C)OC(N[C@](CC1)(CNC2)[C@@H]2[C@@H]1F)=O Chemical compound CC(C)(C)OC(N[C@](CC1)(CNC2)[C@@H]2[C@@H]1F)=O LTYWGNZNVSBEFB-YGOYTEALSA-N 0.000 description 1
- LTYWGNZNVSBEFB-HOTUBEGUSA-N CC(C)(C)OC(N[C@](CC1)(CNC2)[C@@H]2[C@H]1F)=O Chemical compound CC(C)(C)OC(N[C@](CC1)(CNC2)[C@@H]2[C@H]1F)=O LTYWGNZNVSBEFB-HOTUBEGUSA-N 0.000 description 1
- STJOMMKSWSVGSX-NWDGAFQWSA-N CC(C)(C)OC(N[C@](CCC1)(CNC2)[C@]12F)=O Chemical compound CC(C)(C)OC(N[C@](CCC1)(CNC2)[C@]12F)=O STJOMMKSWSVGSX-NWDGAFQWSA-N 0.000 description 1
- WNQQABZMALRECD-YURFNIAASA-N CC(CC(N[C@H](C)N)O)CO Chemical compound CC(CC(N[C@H](C)N)O)CO WNQQABZMALRECD-YURFNIAASA-N 0.000 description 1
- GTIWRANURZKNPL-UHFFFAOYSA-N CC1(C(CC=C)CN(C)C1)C(OC)=O Chemical compound CC1(C(CC=C)CN(C)C1)C(OC)=O GTIWRANURZKNPL-UHFFFAOYSA-N 0.000 description 1
- MNGFVRJNIXNEKQ-FUKIBTTHSA-N CCCCC(CCCC)[C@](CC=C)(CN1[C@H](C)c2ccccc2)[C@H](COCc2ccccc2)C1=O Chemical compound CCCCC(CCCC)[C@](CC=C)(CN1[C@H](C)c2ccccc2)[C@H](COCc2ccccc2)C1=O MNGFVRJNIXNEKQ-FUKIBTTHSA-N 0.000 description 1
- DSPIOEWGEYSYFG-OAHLLOKOSA-N CCCN(C1)CC2=CC=C[C@@]12NC(OC(C)(C)C)=O Chemical compound CCCN(C1)CC2=CC=C[C@@]12NC(OC(C)(C)C)=O DSPIOEWGEYSYFG-OAHLLOKOSA-N 0.000 description 1
- MWVFDPLJUQTHPQ-HDDSUISISA-N CCOC(C(C(c1c2)=O)=CCC[C@H](C(C3)[C@H]3F)c1c(C)c(Br)c2F)=O Chemical compound CCOC(C(C(c1c2)=O)=CCC[C@H](C(C3)[C@H]3F)c1c(C)c(Br)c2F)=O MWVFDPLJUQTHPQ-HDDSUISISA-N 0.000 description 1
- VRTZHPQTMHVKON-ZTMJLAGUSA-N CCOC(C1=CN([C@H](C2)[C@H]2F)c(c(N=C)c(c(F)c2)N(C[C@H]3C(CC4)(F)F)C[C@@]34NC(OC(C)(C)C)=O)c2C1=O)=O Chemical compound CCOC(C1=CN([C@H](C2)[C@H]2F)c(c(N=C)c(c(F)c2)N(C[C@H]3C(CC4)(F)F)C[C@@]34NC(OC(C)(C)C)=O)c2C1=O)=O VRTZHPQTMHVKON-ZTMJLAGUSA-N 0.000 description 1
- MVVJPZWIPRDETG-UHFFFAOYSA-N CN(CC1C=CC=C2)CC12N Chemical compound CN(CC1C=CC=C2)CC12N MVVJPZWIPRDETG-UHFFFAOYSA-N 0.000 description 1
- WEYSGPHVBCGEIT-HHSUGQEISA-N COc(c([C@H](CCC=C1C(O)=O)C(C2)[C@H]2F)c(cc2F)C1=O)c2N(C[C@H]1[C@H](CC2)F)C[C@@]12N Chemical compound COc(c([C@H](CCC=C1C(O)=O)C(C2)[C@H]2F)c(cc2F)C1=O)c2N(C[C@H]1[C@H](CC2)F)C[C@@]12N WEYSGPHVBCGEIT-HHSUGQEISA-N 0.000 description 1
- ZZTBNWKCDVAMRE-UHFFFAOYSA-N COc1c(CCC(CC2OCCC3)CC23N)c(F)cc(C2O)c1N(C1CC1)C=C2C(O)=O Chemical compound COc1c(CCC(CC2OCCC3)CC23N)c(F)cc(C2O)c1N(C1CC1)C=C2C(O)=O ZZTBNWKCDVAMRE-UHFFFAOYSA-N 0.000 description 1
- RAIJRODVEYZQJJ-LLVKDONJSA-N C[C@H](c1ccccc1)N(CC1=C=CC=C11)C1=O Chemical compound C[C@H](c1ccccc1)N(CC1=C=CC=C11)C1=O RAIJRODVEYZQJJ-LLVKDONJSA-N 0.000 description 1
- MYSRUUFMJLRZOY-VNQPRFMTSA-N C[C@H](c1ccccc1)N(C[C@@H]1CC=CC2)C[C@@]12N Chemical compound C[C@H](c1ccccc1)N(C[C@@H]1CC=CC2)C[C@@]12N MYSRUUFMJLRZOY-VNQPRFMTSA-N 0.000 description 1
- NGTHNNQBZCNNKI-ZIAGYGMSSA-N C[C@H](c1ccccc1)N(C[C@H](CC(C)=C)C1)C1=O Chemical compound C[C@H](c1ccccc1)N(C[C@H](CC(C)=C)C1)C1=O NGTHNNQBZCNNKI-ZIAGYGMSSA-N 0.000 description 1
- AGTRJVFASFKUPF-UHFFFAOYSA-N O=C1C(CNI)OCCC1 Chemical compound O=C1C(CNI)OCCC1 AGTRJVFASFKUPF-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JPJP-P-2007-000667 | 2007-01-05 | ||
| JP2007000667 | 2007-01-05 | ||
| JPJP-P-2007-074991 | 2007-03-22 | ||
| JP2007074991 | 2007-03-22 | ||
| PCT/JP2007/075434 WO2008082009A2 (en) | 2007-01-05 | 2007-12-28 | Fused substituted aminopyrrolidine derivative |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20090096618A KR20090096618A (ko) | 2009-09-11 |
| KR101419085B1 true KR101419085B1 (ko) | 2014-07-15 |
Family
ID=39522355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020097013835A Expired - Fee Related KR101419085B1 (ko) | 2007-01-05 | 2007-12-28 | 융합 치환된 아미노피롤리딘 유도체 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8618094B2 (enExample) |
| EP (2) | EP2540715A1 (enExample) |
| JP (1) | JP5197606B2 (enExample) |
| KR (1) | KR101419085B1 (enExample) |
| AR (1) | AR064753A1 (enExample) |
| AU (1) | AU2007339692B2 (enExample) |
| BR (1) | BRPI0720771A2 (enExample) |
| CA (1) | CA2674369C (enExample) |
| CL (1) | CL2008000026A1 (enExample) |
| CY (1) | CY1114444T1 (enExample) |
| DK (1) | DK2097400T3 (enExample) |
| ES (1) | ES2428344T3 (enExample) |
| IL (1) | IL199694A (enExample) |
| MX (1) | MX2009007291A (enExample) |
| MY (1) | MY162052A (enExample) |
| NO (1) | NO20092804L (enExample) |
| NZ (1) | NZ577214A (enExample) |
| PE (1) | PE20081631A1 (enExample) |
| PL (1) | PL2097400T3 (enExample) |
| PT (1) | PT2097400E (enExample) |
| RU (1) | RU2443698C2 (enExample) |
| SI (1) | SI2097400T1 (enExample) |
| TW (1) | TWI409068B (enExample) |
| WO (1) | WO2008082009A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201210595A (en) | 2010-08-06 | 2012-03-16 | Daiichi Sankyo Co Ltd | A crystal of antibacterial compound |
| WO2014152317A2 (en) * | 2013-03-15 | 2014-09-25 | Melinta Therapeutics, Inc. | Methods of treating gonorrhea infections using quinolone antibiotics |
| SI3413892T1 (sl) | 2016-02-12 | 2022-06-30 | Cytokinetics, Incorporated | Tetrahidroizokinolinski derivati |
| TW202128645A (zh) * | 2019-10-23 | 2021-08-01 | 太景生物科技股份有限公司 | 喹諾酮羧酸衍生物 |
| KR20240141704A (ko) * | 2021-07-22 | 2024-09-27 | 더 텍사스 에이 & 엠 유니버시티 시스템 | 활성화된 페레이트 용액 및 이의 방법 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0343524A1 (en) * | 1988-05-23 | 1989-11-29 | Shionogi Seiyaku Kabushiki Kaisha | Pyridonecarboxylic acids and antibacterial agents |
| WO1995021163A1 (en) | 1994-02-04 | 1995-08-10 | Dainippon Pharmaceutical Co., Ltd. | Pyridonecarboxylic acid derivative substituted by bicyclic amino group, ester thereof, salt thereof, and bicyclic amine as intermediate therefor |
| WO1996023782A1 (en) | 1995-02-02 | 1996-08-08 | Daiichi Pharmaceutical Co., Ltd. | Heterocyclic compounds |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61282382A (ja) | 1985-06-06 | 1986-12-12 | Dainippon Pharmaceut Co Ltd | フエニル置換１，８−ナフチリジン誘導体、そのエステルおよびその塩 |
| EP0242789A3 (en) | 1986-04-25 | 1990-09-05 | Dainippon Pharmaceutical Co., Ltd. | Novel quinoline derivates and processes for preparation thereof |
| JPH0676400B2 (ja) * | 1987-08-25 | 1994-09-28 | 大日本製薬株式会社 | 新規ピリドンカルボン酸誘導体、そのエステルおよびその塩 |
| MY105136A (en) | 1988-04-27 | 1994-08-30 | Daiichi Seiyaku Co | Optically active pyridonecarboxylic acid derivatives. |
| JP2807277B2 (ja) | 1988-08-31 | 1998-10-08 | 第一製薬株式会社 | スピロ化合物 |
| JPH0278659A (ja) * | 1988-09-12 | 1990-03-19 | Shionogi & Co Ltd | アザビシクロアルカン類化合物 |
| WO1994014794A1 (fr) | 1992-12-28 | 1994-07-07 | Yoshitomi Pharmaceutical Industries, Ltd. | Derive d'acide 8-methoxyquinolonecarboxylique |
| JPH06345261A (ja) | 1993-04-16 | 1994-12-20 | Daihen Corp | 自動搬送装置の搬送用ハンド |
| DE4435479A1 (de) | 1994-10-04 | 1996-04-11 | Bayer Ag | Chinolon- und Naphthyridoncarbonsäure-Derivate |
| CA2222322A1 (en) * | 1995-06-06 | 1996-12-12 | Abbott Laboratories | Quinolizinone type compounds |
| JP4132155B2 (ja) * | 1996-10-25 | 2008-08-13 | 第一三共株式会社 | 三環性アミン誘導体 |
| ATE297912T1 (de) * | 1998-11-24 | 2005-07-15 | Daiichi Seiyaku Co | Cycloalkylsubstituierte aminomethylpyrrolidin- derivate |
| WO2002042312A1 (en) * | 2000-11-24 | 2002-05-30 | Meiji Seika Kaisha, Ltd. | Novel carbapenem derivatives |
| WO2005049602A1 (en) * | 2003-11-18 | 2005-06-02 | Warner-Lambert Company Llc | Quinolone antibacterial agents |
| US7563805B2 (en) * | 2005-05-19 | 2009-07-21 | Daiichi Pharmaceutical Co., Ltd. | Tri-, tetra-substituted-3-aminopyrrolidine derivative |
-
2007
- 2007-12-28 NZ NZ577214A patent/NZ577214A/en not_active IP Right Cessation
- 2007-12-28 DK DK07860629.0T patent/DK2097400T3/da active
- 2007-12-28 PL PL07860629T patent/PL2097400T3/pl unknown
- 2007-12-28 KR KR1020097013835A patent/KR101419085B1/ko not_active Expired - Fee Related
- 2007-12-28 EP EP12186361A patent/EP2540715A1/en not_active Withdrawn
- 2007-12-28 MX MX2009007291A patent/MX2009007291A/es active IP Right Grant
- 2007-12-28 AU AU2007339692A patent/AU2007339692B2/en not_active Ceased
- 2007-12-28 BR BRPI0720771-9A2A patent/BRPI0720771A2/pt not_active IP Right Cessation
- 2007-12-28 EP EP07860629.0A patent/EP2097400B1/en not_active Not-in-force
- 2007-12-28 SI SI200731318T patent/SI2097400T1/sl unknown
- 2007-12-28 RU RU2009129975/04A patent/RU2443698C2/ru not_active IP Right Cessation
- 2007-12-28 ES ES07860629T patent/ES2428344T3/es active Active
- 2007-12-28 PT PT78606290T patent/PT2097400E/pt unknown
- 2007-12-28 CA CA2674369A patent/CA2674369C/en not_active Expired - Fee Related
- 2007-12-28 MY MYPI20092809A patent/MY162052A/en unknown
- 2007-12-28 WO PCT/JP2007/075434 patent/WO2008082009A2/en not_active Ceased
- 2007-12-28 JP JP2009527641A patent/JP5197606B2/ja not_active Expired - Fee Related
-
2008
- 2008-01-03 TW TW097100126A patent/TWI409068B/zh not_active IP Right Cessation
- 2008-01-04 PE PE2008000090A patent/PE20081631A1/es not_active Application Discontinuation
- 2008-01-04 CL CL200800026A patent/CL2008000026A1/es unknown
- 2008-01-04 AR ARP080100035A patent/AR064753A1/es not_active Application Discontinuation
-
2009
- 2009-07-02 US US12/459,612 patent/US8618094B2/en not_active Expired - Fee Related
- 2009-07-05 IL IL199694A patent/IL199694A/en not_active IP Right Cessation
- 2009-08-04 NO NO20092804A patent/NO20092804L/no not_active Application Discontinuation
-
2013
- 2013-09-30 CY CY20131100845T patent/CY1114444T1/el unknown
- 2013-11-19 US US14/084,485 patent/US20140142096A1/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0343524A1 (en) * | 1988-05-23 | 1989-11-29 | Shionogi Seiyaku Kabushiki Kaisha | Pyridonecarboxylic acids and antibacterial agents |
| WO1995021163A1 (en) | 1994-02-04 | 1995-08-10 | Dainippon Pharmaceutical Co., Ltd. | Pyridonecarboxylic acid derivative substituted by bicyclic amino group, ester thereof, salt thereof, and bicyclic amine as intermediate therefor |
| EP0812838A1 (en) * | 1994-02-04 | 1997-12-17 | Dainippon Pharmaceutical Co., Ltd. | Pyridonecarboxylic acid derivative substituted by bicyclic amino group, ester thereof, salt thereof, and bicyclic amine as intermediate therefor |
| WO1996023782A1 (en) | 1995-02-02 | 1996-08-08 | Daiichi Pharmaceutical Co., Ltd. | Heterocyclic compounds |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109996792B (zh) | 在治疗cns疾病和疼痛中具有作为毒蕈碱性m1和/或m4受体调节剂活性的杂环化合物 | |
| TW202309051A (zh) | 食慾素受體促效劑及其用途 | |
| KR101419085B1 (ko) | 융합 치환된 아미노피롤리딘 유도체 | |
| EP1304329A2 (en) | Pyridonecarboxylic acid derivatives and their use as antibacterial agents | |
| CN101622240B (zh) | 稠合取代氨基吡咯烷衍生物 | |
| AU2006248354B2 (en) | Tri- or tetra-substituted-3-aminopyrrolidine derivatives | |
| US6384050B1 (en) | Tricyclic amine derivatives | |
| MXPA04009026A (es) | Derivados de acido 10- (3- ciclopropilaminometil -1-pirrolidinil) piridobenzoxazin- carboxilico efectivos contra bacterias resistentes a farmacos. | |
| WO1997019072A1 (en) | Substituted aminocycloalkylpyrrolidine derivatives | |
| AU2022215616A1 (en) | Quinoxaline derivatives and uses thereof | |
| RU2131430C1 (ru) | Производные пиридобензоксадиазина, смесь их изомеров или отдельные изомеры, их гидраты и соли | |
| TW201109339A (en) | 3-(biaryloxy) propionic acid derivative | |
| JP2024540478A (ja) | クロマンアミジンモノバクタム抗生物質 | |
| JP2010031000A (ja) | フューズ置換型アミノピロリジン誘導体含有医薬組成物 | |
| HK1130056B (en) | Fused substituted aminopyrrolidine derivative | |
| JP7671398B2 (ja) | クロマンアミジンモノバクタム抗生物質 | |
| EP2674430A1 (en) | Amino group-containing pyrrolidinone derivative | |
| JPH1112278A (ja) | ピリドンカルボン酸誘導体、そのエステルまたはこれらの塩 | |
| HK40041233A (en) | Sulphonyl urea derivatives as nlrp3 inflammasome modulators | |
| HK40042117A (en) | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| LAPS | Lapse due to unpaid annual fee | ||
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20170708 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20170708 |